Foghorn Therapeutics Inc

NASDAQ:FHTX 4:00:00 PM EDT

5.21

+0.05 (+0.97%)

4:30:02 PM EDT: $5.13 -0.08 (-1.54%)

Market Cap (Intraday)	221.77M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$6.86 Million
Adjusted EPS	-$0.62

See more estimates

10-Day MA	$5.76
50-Day MA	$6.55
200-Day MA	$5.89

See more pivots

Foghorn Therapeutics Inc Stock, NASDAQ:FHTX

500 Technology Square, Suite 700, Cambridge, Massachusetts 02139

United States of America

Phone: +1.617.586.3100

Number of Employees: 116

http://www.foghorntx.com

Description

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.